Graphico

Graphico Net Debt / EBITDA

Delisted

The Net Debt to EBITDA of Graphico (4930.T) as of Nov 17, 2026 is 0.60. In the previous year, Net Debt to EBITDA was -0.47 — a change of -230.00% (higher).

Net Debt / EBITDA

0.60

YoY

-230.00%

Last updated:

Net Debt to EBITDA of Graphico is 2023 0.60 . Net Debt to EBITDA of Graphico was 2022 -0.47 . It decreases by -230.00% higher compared to the previous year.

The Graphico Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2014
-1.58 JPY
Jan 1, 2015
-3.01 JPY
Jan 1, 2018
-0.03 JPY
Jan 1, 2019
-1.04 JPY
Jan 1, 2020
-1.65 JPY
Jan 1, 2021
-2.06 JPY
Jan 1, 2022
-0.47 JPY
Jan 1, 2023
0.60 JPY
The Graphico Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.60-230.00%
-0.47-77.45%
-2.06+24.76%
-1.65+58.60%
-1.04+3,338.50%
-0.03-98.99%
-3.01+90.19%
-1.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Graphico Stock analysis

What does Graphico do? Graphico Inc. generates revenue through the sale of health foods, cosmetics, ethical drugs, over-the-counter drugs, and household products via drug stores, general merchandise stores, home centers, variety stores, and mail-order channels. The company outsources manufacturing and logistics while focusing on product planning, development, marketing, and sales. Its main product categories include healthcare centered on health foods, beauty care centered on cosmetics, and ethical and over-the-counter drugs. Overseas sales are handled through country-specific distributors. The company targets consumers seeking health and beauty solutions through established retail channels and direct mail-order services. Product planning and development are central to its strategy, with a focus on health foods, cosmetics, and pharmaceuticals. The firm operates as a fabless business model, relying on external partners for manufacturing and logistics to maintain agility in product innovation. Graphico Inc. serves multiple segments including health-conscious women, beauty care consumers, and individuals seeking over-the-counter medications. Sales channels include drug stores, GMS, home centers, variety stores, and mail-order systems. The company's overseas presence is supported by distributors in each country, enabling global market access without direct operational infrastructure. Graphico is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Graphico stock

Net Debt to EBITDA of Graphico is 0.60 in 2023.

Net Debt to EBITDA of Graphico changed from -0.47 to 0.60, representing a -230.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Graphico since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Graphico with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Graphico

All Key Metrics — Graphico